Drugs / Nanocoll
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04261179 | Mar 2020 → Feb 2021 | breast cancer, malignant tumor of neck, melanoma | Anna Cruceta | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanocoll | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04261179 ↗ |
| Modality | Diagnostic / imaging agent | “for Image- Guided Sentinel Lymph Node Mapping” NCT04261179 ↗ |